Evidence map›Paper›PMID 35466278›Full record

ReviewAntibodies (Basel, Switzerland)2022

Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C-Can We Match the Puzzle?

Snezhina Lazova, Yulia Dimitrova, Diana Hristova, Iren Tzotcheva, Tsvetelina Velikova

Open access · goldAbstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Snezhina LazovaPediatric Department, University Hospital "N. I. Pirogov", 21 "General Eduard I. Totleben", Blvd., 1463 Sofia, Bulgaria.ORCID 0000-0002-5884-7760
Yulia DimitrovaPediatric Department, University Hospital "N. I. Pirogov", 21 "General Eduard I. Totleben", Blvd., 1463 Sofia, Bulgaria.
Diana HristovaDepartment of Immunology, National Center of Infectious and Parasitic Diseases, 1504 Sofia, Bulgaria.ORCID 0000-0002-9710-1312
Iren TzotchevaPediatric Department, University Hospital "N. I. Pirogov", 21 "General Eduard I. Totleben", Blvd., 1463 Sofia, Bulgaria.
Tsvetelina VelikovaDepartment of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Kozyak 1 Str., 1407 Sofia, Bulgaria.ORCID 0000-0002-0593-1272
National Institute of Emergency Medicine "Pirogov" · BGLozenetz Hospital · BGMedical University of Sofia · BGNational Center of Infectious and Parasitic Diseases · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The newly identified strain of the Coronaviridae family called severe acute respiratory syndrome (SARS-CoV-2) recently became the most significant health threat for adults and children. Some main predictors of severe clinical course in patients with SARS-CoV-2 infection are age and concomitant health conditions. Therefore, the proper evaluation of SARS-CoV-2-specific immunity is urgently required to understand and predict the spectrum of possible clinical phenotypes and recommend vaccination options and regimens in children. Furthermore, it is critical to characterize the nature of SARS-CoV-2-specific immune responses in children following asymptomatic infection and COVID-19 and other related conditions such as multisystem inflammatory syndrome (MIS-C), para-infectious and late postinfectious consequences. Recent studies involving children revealed a variety of cytokines, T cells and antibody responses in the pathogenesis of the disease. Moreover, different clinical scenarios in children were observed-asymptomatic seroprevalence, acute SARS-CoV-2 infection, and rarely severe COVID-19 with typical cytokine storm, MIS-C, long COVID-19, etc. Therefore, to gain a better clinical view, adequate diagnostic criteria and treatment algorithms, it is essential to create a realistic picture of the immunological puzzle of SARS-CoV-2 infection in different age groups. Finally, it was demonstrated that children may exert a potent and prolonged adaptive anti-SARS-CoV-2 immune response, with significant cross-reactions against other human Corona Viruses, that might contribute to disease sparing effect in this age range. However, the immunopathology of the virus has to be elucidated first.

Indexed as

antibodiesB cellscell-mediated immunityCOVID-19cytokineMIS-CSARS-CoV-2SARS-CoV-2 specific immunityT cells

Identifiers

PMID35466278
PMCPMC9036295
OpenAlexW4224435377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.